Tags : Finch Therapeutics

Takeda Expands its Collaboration with Finch Therapeutics to Develop Microbiome

Shots: Finch and Takeda will leverage Finch’s platform to develop microbiome-based therapeutics targeting Crohn’s disease. Takeda to get exclusive worldwide rights to commercialize rationally selected microbiota (RSM) therapies developed for Crohn’s disease In 2107, Takeda and Finch collaborated to jointly develop FIN-524 for ulcerative colitis under which Finch has received $10M upfront, milestones & royalties […]Read More

Finch Therapeutics’ CP101 Receives FDA’s Breakthrough Therapy Designation (BT) for

Shots: The FDA’s BT designation follows P-II PRISM3 study results assessing CP101 vs PBO in patients with recurrent C. difficile FDA’s BT designation is granted to the drugs showing clinical improvement over currently available therapy in serious or life-threatening conditions on at least one clinically significant endpoint with benefits of Priority Review and accelerated approval […]Read More